Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.895 EUR | +5.29% | +13.29% | +68.87% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
- With regards to fundamentals, the enterprise value to sales ratio is at 0.9 for the current period. Therefore, the company is undervalued.
- The company's share price in relation to its net book value makes it look relatively cheap.
- The company is one of the best yield companies with high dividend expectations.
- Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+68.87% | 692M | - | ||
+16.93% | 42.79B | B- | ||
+22.20% | 22.81B | B+ | ||
+16.96% | 15.04B | - | ||
+18.51% | 14.49B | B+ | ||
+51.63% | 12.65B | B | ||
-0.05% | 6.79B | - | - | |
-11.45% | 6.74B | B+ | ||
-8.87% | 5.73B | - | - | |
+14.55% | 5.47B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1681 Stock
- C1P Stock
- Ratings Consun Pharmaceutical Group Limited